Top in endocrinology: COVID-19 vaccine response, fracture risk for women with obesity
Central obesity, smoking, hypertension and dislipidemia were associated with fewer COVID-19 antibodies in people receiving the Pfizer-BioNTech COVID-19 vaccine, according to recent data.
A review of the report was the top story in endocrinology last week.
Another top story was about a study that found women with obesity had higher volumetric bone mineral density and femoral bone strength compared with women of a normal weight. The researchers said this finding could change how clinicians approach fracture risk for patients with obesity.
Read these and more top stories in endocrinology below:
Smoking, central obesity, hypertension may lower antibody response to COVID-19 vaccine
Compared with healthy adults, those who smoke or have central obesity or hypertension may produce fewer antibodies following Pfizer-BioNTech COVID-19 vaccination, according to a study published in Diabetes/Metabolism Research and Reviews. Read more.
Stronger hip structure, greater BMD observed in young women with obesity vs normal weight
Young women with obesity have a higher areal bone mineral density, better hip structure and higher volumetric bone mineral density in all femoral compartments compared with women with normal weight, according to a study published in Bone. Read more.
Biden administration proposes rescinding rule on community health center insulin discounts
The Biden administration proposed rescinding a final rule introduced under the Trump administration that would require community health centers to pass on 340B drug discounts for insulin and injectable epinephrine to low-income patients. Read more.
Children’s Hospital of Philadelphia tops pediatric diabetes, endocrinology rankings
Children’s Hospital of Philadelphia was once again named the No. 1 hospital in the country for pediatric diabetes and endocrinology by the U.S. News & World Report 2021-2022 Best Children’s Hospitals rankings. Read more.
ADA updates standards of care to reflect new teplizumab, HF data
The American Diabetes Association issued updates to the 2021 Standards of Medical Care in Diabetes to reflect new data on the immunotherapy teplizumab for type 1 diabetes and heart failure benefits seen with SGLT2 inhibitors. Read more.